Novel Immunotherapeutic Avenues for Rheumatoid Arthritis

详细信息    查看全文

• 作者：Luca Semerano¹ ; ² ; ³ ; Emeline Minichiello² ; ³ ; Natacha Bessis¹ ; ² ; Marie-Christophe Boissier¹ ; ² ; ³ ; ^{marie-christophe.boissier@aphp.fr" class="auth_mail" title="E-mail the corresponding author}
• 刊名：Trends in Molecular Medicine
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：22
• 期：3
• 页码：214-229
• 全文大小：2643 K

文摘

Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease. It leads to irreversible joint damage, physical handicap, and reduced life expectancy. The past two decades have seen considerable therapeutic advances with the development of biologic treatments to block proinflammatory cytokines or modulate lymphocyte function, followed by the development of small molecules to target intracellular signaling. Nevertheless, only a minority of patients can achieve disease remission, especially long term, warranting further investigation into newer therapeutic options. Targeting single proinflammatory pathways may not be sufficient, as suggested by variable results with T helper (Th)-17-related cytokine blockade. Multilevel information from ‘omics’ techniques along with data from mechanistic studies might facilitate the identification of pivotal checkpoints in RA disease pathogenesis and the subsequent development of new effective treatments.